ATE358486T1 - Verwendung von xestospongin c zur behandlung oder vorbeugung einer hiv-infektion - Google Patents
Verwendung von xestospongin c zur behandlung oder vorbeugung einer hiv-infektionInfo
- Publication number
- ATE358486T1 ATE358486T1 AT01983374T AT01983374T ATE358486T1 AT E358486 T1 ATE358486 T1 AT E358486T1 AT 01983374 T AT01983374 T AT 01983374T AT 01983374 T AT01983374 T AT 01983374T AT E358486 T1 ATE358486 T1 AT E358486T1
- Authority
- AT
- Austria
- Prior art keywords
- xestospongin
- treat
- hiv infection
- receptor
- calcium channel
- Prior art date
Links
- 208000031886 HIV Infections Diseases 0.000 title 1
- 208000037357 HIV infectious disease Diseases 0.000 title 1
- PQYOPBRFUUEHRC-UHFFFAOYSA-N ent-xestospongin A Natural products C1CCCCCC(OC23)CCN3CCCC2CCCCCCC(O2)CCN3C2C1CCC3 PQYOPBRFUUEHRC-UHFFFAOYSA-N 0.000 title 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 title 1
- PQYOPBRFUUEHRC-MUJQFDPKSA-N xestospongin c Chemical compound C([C@@H]1CCCN2CC[C@@H](O[C@H]12)CCCCCC1)CCCCC[C@H](O2)CCN3[C@H]2[C@@H]1CCC3 PQYOPBRFUUEHRC-MUJQFDPKSA-N 0.000 title 1
- 229940127291 Calcium channel antagonist Drugs 0.000 abstract 3
- 108091008585 IP3 receptors Proteins 0.000 abstract 3
- 102000007640 Inositol 1,4,5-Trisphosphate Receptors Human genes 0.000 abstract 3
- 239000000480 calcium channel blocker Substances 0.000 abstract 3
- 230000001404 mediated effect Effects 0.000 abstract 3
- 102000003945 NF-kappa B Human genes 0.000 abstract 2
- 108010057466 NF-kappa B Proteins 0.000 abstract 2
- 230000004913 activation Effects 0.000 abstract 2
- 208000036142 Viral infection Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037765 diseases and disorders Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000037824 growth disorder Diseases 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Biotechnology (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24676300P | 2000-11-09 | 2000-11-09 | |
| US09/878,918 US20020107193A1 (en) | 2000-11-09 | 2001-06-13 | Therapeutic uses for IP3 receptor-mediated calcium channel modulators |
| US30786001P | 2001-07-27 | 2001-07-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE358486T1 true ATE358486T1 (de) | 2007-04-15 |
Family
ID=27399962
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT01983374T ATE358486T1 (de) | 2000-11-09 | 2001-11-08 | Verwendung von xestospongin c zur behandlung oder vorbeugung einer hiv-infektion |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP1331932B1 (de) |
| AT (1) | ATE358486T1 (de) |
| AU (1) | AU2002214886A1 (de) |
| CA (1) | CA2427757A1 (de) |
| DE (1) | DE60127703D1 (de) |
| WO (1) | WO2002038140A2 (de) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1444981A1 (de) * | 2001-10-11 | 2004-08-11 | Katsuhiko Mikoshiba | Mittel zur unterdrückung der zunahme der intrazellulären calciumkonzentration |
| JP5360635B2 (ja) * | 2005-11-25 | 2013-12-04 | 独立行政法人科学技術振興機構 | 新規ビスホウ素化合物 |
| CA2642508C (en) | 2008-10-31 | 2011-10-04 | Kenneth W. Adams | Method of removal of hyperplastic skin lesions |
| CA2687013C (en) | 2009-12-03 | 2018-09-04 | Kenneth W. Adams | Method and composition for treatment and prevention of broad spectrum virus ailments |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS59227885A (ja) * | 1983-06-09 | 1984-12-21 | Suntory Ltd | １−オキサキノリチジン類 |
| EP0355905B1 (de) * | 1988-08-24 | 1993-01-07 | Akzo N.V. | Fragmente und Fraktionen von Heparin mit Wirkung gegen HIV |
| US5276182A (en) * | 1990-07-09 | 1994-01-04 | The Dow Chemical Company | Process for preparing polyurea oligomers |
| DK0520372T3 (da) * | 1991-06-26 | 1997-05-12 | Hoechst Ag | Inositol-phosphat-analoger som calciumantagonistiske stoffer |
| AU670962B2 (en) * | 1992-09-28 | 1996-08-08 | Merrell Dow Pharmaceuticals Inc. | Method for antagonizing inositol 1,4,5-triphosphate |
| GB9515469D0 (en) * | 1995-07-28 | 1995-09-27 | Pharma Mar Sa | Bis-1-oxaquinolizidine alkaloids from a marine sponge with antitumor activity |
| US6465211B1 (en) * | 1998-08-27 | 2002-10-15 | Riken | Nucleic acids, vectors and transformed cells for making and using high affinity IP-3 binding polypeptides |
| US6027731A (en) * | 1998-11-17 | 2000-02-22 | Wisconsin Alumni Research Foundation | Pertussis toxin induced lymphocytosis |
-
2001
- 2001-11-08 CA CA002427757A patent/CA2427757A1/en not_active Abandoned
- 2001-11-08 AT AT01983374T patent/ATE358486T1/de not_active IP Right Cessation
- 2001-11-08 EP EP01983374A patent/EP1331932B1/de not_active Expired - Lifetime
- 2001-11-08 WO PCT/CA2001/001575 patent/WO2002038140A2/en not_active Ceased
- 2001-11-08 DE DE60127703T patent/DE60127703D1/de not_active Expired - Lifetime
- 2001-11-08 AU AU2002214886A patent/AU2002214886A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2002214886A1 (en) | 2002-05-21 |
| EP1331932A2 (de) | 2003-08-06 |
| CA2427757A1 (en) | 2002-05-16 |
| WO2002038140A2 (en) | 2002-05-16 |
| DE60127703D1 (de) | 2007-05-16 |
| WO2002038140A3 (en) | 2003-03-13 |
| EP1331932B1 (de) | 2007-04-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2160597T3 (es) | Tratamiento y profilaxis de enfermedades producidas por parasitos o bacterias. | |
| DE59409832D1 (de) | Pflaster zur behandlung von nagelmykosen | |
| ATE415962T1 (de) | Verwendung von asiatsäure oder asiaticosid zur behandlung von krebs | |
| DE60115000D1 (de) | Die Verwendung von Prostaglandin F Analoga zur Herstellung von Zusammensetzungen für die Behandlung von Haarausfall. | |
| ATE254461T1 (de) | Behandlung von augenschmerzen | |
| ATE422357T1 (de) | Verwendung von allopurinol zur behandlung von bluthochdruck | |
| DE60127703D1 (de) | Verwendung von xestospongin c zur behandlung oder vorbeugung einer hiv-infektion | |
| WO2023240199A3 (en) | Fitusiran for the treatment of hemophilia a and b | |
| ATE332688T1 (de) | Verwendung von carbinolen zur behandlung von neuropathischer funktionsstörung | |
| ATE401888T1 (de) | Verwendung von tigecyclin, allein oder in kombination mit rifampin zur behandlung von osteomyelitis und/oder septischer arthritis | |
| NO20032406L (no) | Anvendelse av 1-fenyl-3-dimetylaminopropanforbindelser for behandling av urininkontinens | |
| DE50100833D1 (de) | Verwendung von 2-methyl-thiazolidin-2,4-dicarbonsäure und / oder ihrer physiologisch verträglichen salze zur herstellung eines medikaments zur behandlung von krebserkrankungen | |
| ATE361071T1 (de) | Verwendung von irbesartan zur vorbeugung oder behandlung pulmonaler hypertonie | |
| ATE542542T1 (de) | Verwendung von gp130 aktivatoren zur behandlung von diabetischer neuropathie | |
| ATE270895T1 (de) | Topische verwendung von ätherischen ölen zur behandlung von wundheilungsstörungen | |
| ATE302009T1 (de) | Ubichinon qn zur behandlung von migräneschmerzen | |
| DE59910542D1 (de) | Verwendung von diminazen-di-aceturat und/oder pentamidin zur behandlung von malaria | |
| WO2025147672A3 (en) | Compositions and methods of use thereof | |
| DE50105253D1 (de) | Verwendung von n-oleoylethanolamin zur behandlung der schuppenflechte (psoriasis) | |
| DE60108241D1 (de) | Felabamat-derivate zur behandlung von neuropathischem schmerz | |
| DE10080190D2 (de) | Mittel zur Prävention und/oder Behandlung einer Gewebeveränderung mesenchymalen Ursprungs | |
| DE50107498D1 (de) | Verwendung einer zubereitung zur topischen behandlung von durch virusinfektionen verursachten manifestationen | |
| TW202547533A (zh) | 用非妥西蘭治療血友病 | |
| DE60233353D1 (de) | Verfahren zur behandlung von halitose | |
| UA42335A (uk) | Спосіб лікування гнійних ран |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |